Hana Biosciences is a company that is clearly moving in the right direction. The company’s lead product candidate, Marquibo, has been developed to help all cancer patients battle the deadly disease and with news released today, the concept has a great deal of backing.

The young California Company announced there is a definite agreement in place with accredited investors to sell units consisting of common stocks and warrants which will result in total cash proceeds of $12.4 million the closing of which is expected to occur prior to October 9th with Piper Jaffray and Co. serving as exclusive place agent for the transaction.

The net proceeds of this offering will be used to support the completion of the pivotal Phase 2 clinical trial of Marquibo in adult patients with Philadelphia Chromosome negative acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma in second relapse or who failed two prior lines of treatment. The

...

Bio-Matrix Scientific Group Inc., a biotech research and development company, recently made a joint announcement with its subsidiary Entest BioMedical Inc. (ENTB.OB), a testing center for various diseases, that they have reached a definitive agreement with Therinject LLC for the development of a immune-therapeutic cancer vaccine.

The companies will first focus on the veterinary market, treating animals with tumors. It’s a market that Bio-Matrix chairman and CEO David Koos says is a significant one. The company anticipates treating thousands of animals, generating millions in revenues.

“Cancer is the No. 1 cause of death among dogs. It’s estimated that one out of every three dogs will get cancer. We anticipate this immuno-therapeutic cancer vaccine could have an efficacy rate of as high as 60 percent where 15 percent to 20 percent is the current cure rate,” Koos stated in the press release. “We believe that during the first year this

...

For Immediate Release

Chicago, IL – August 27, 2009 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: United Heathcare Group (UNH), Aetna (AET), Wet Seal Inc. (WTSLA), VeriSign Inc. (VRSN) and Syniverse Holdings Inc. (SVR).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513

Here are highlights from Wednesday’s Analyst Blog:

CBO Overstates Healthcare Costs

Some of the more outrageous types of misconduct by the likes of United Heathcare Group (UNH) and Aetna (AET) might be curbed, such as the cancelling of policies as soon as someone gets sick and puts in a substantial

...

Yesterday, Bristol-Myers Squibb Co. (BMY) extended its cash tender offer to purchase all outstanding shares of Medarex Inc. (MEDX) by two days to Aug. 26. Bristol-Myers offered to buy Medarex for $16 per share, or $2.1 billion in July. However, less than 9% of Medarex's outstanding shares have been tendered till now. Last week, antitrust regulators approved the deal.

With the acquisition of Medarex, Bristol-Myers will get the UltiMAb Human Antibody Development System, which produces high affinity, human antibodies for use in a broad range of therapeutic areas, including immunology and oncology. It will also obtain Medarex’s next-generation Antibody-Drug Conjugate (ADC) technology, which is a novel and proprietary platform that could open new fields in cancer treatment.

Medarex’s has seven antibodies in clinical trials under its sole funding and is developing three other antibodies under partnership contracts. Importantly, Bristol-Myers will acquire full ownership and rights to ipilimumab,

...

PennyOmega.com Stock Report!

PennyOmega.com Hot Stock News & Alerts!

 

Wednesday August 5, 2009

PennyOmega.com Stock Report!

**************************************************************

TomoTherapy Incorporated (NASDAQ: TOMO) announced today that the 2009 meeting of the American Association of Physicists in Medicine (AAPM) featured a comprehensive look at the current and future role of TomoTherapy® technology in addressing complex cancer treatment challenges. TomoTherapy users from around the world attended the AAPM annual meeting, presenting on topics that addressed: the successful use of TomoTherapy’s unique radiation therapy solution across a wide range of cases; planning studies documenting the clinical advantages of TomoTherapy over treatments from conventional radiation therapy devices; and investigations into radiobiological treatment improvements using the unique CT scanner-based TomoTherapy platform.

China Bio Energy

...

On Jul 15, 2009, Colorado-based biopharmaceutical company Array BioPharma Inc. (ARRY) filed an investigational new drug application (NDA) with the objective of initiating a phase I trial in cancer patients with its most advanced, wholly-owned MEK inhibitor, ARRY-162.

The open-label, multiple dose study is designed to evaluate the tolerability, safety and efficacy of the inhibitor following the oral administration of the drug to advanced cancer patients with solid tumors on a daily basis. The study is expected to commence in the third quarter of 2009.

Array is also evaluating the candidate for arthritis and chronic obstructive pulmonary disease (COPD). Currently, a worldwide phase II, double-blinded study (n=200) for ARRY-162 with active rheumatoid arthritis is in progress.

We think that Array's decision to evaluate its most advanced MEK inhibitor in the field of cancer will benefit cancer patients immensely. Further, management believes that ARRY-162 is not only well-suited for cancer treatment but

...

Oncology market is witnessing considerable growth and attracting large investments from many big pharmaceutical companies to increase their presence. Pfizer (PFE) aims big in the oncology market, which is mainly dominated by Roche and expects its global medicine sale for cancer to increase ten-fold by 2018.

The company plans to become the third largest player (from current seventh) in cancer medicine, which contributed about $2.5 billion of sales in 2008. At present, many of its products under clinical trial are for cancer treatment and six more will be added from the acquisition of Wyeth.

A number of factors such as high unmet need, favorable demographics, increased life expectancy and aging population are responsible for the renewed interest in this area. The anti-cancer drug market value is expected to grow to $85 billion in 2013 from $67 billion in 2008. Leading products for cancer therapy (fifth-largest therapeutic class globally) include MabThera/Rituxan, Herceptin

...

Viral Genetics, Inc., a company that develops drug compounds to treat cancer, Lyme Disease, and HIV, has received a patent for cancer treatment therapies. This patent protects cancer drugs that have used mice as clinical research subjects. Issued on March 31, 2009, the U.S. Patent Number is: 7,510,710.

M. Karen Newell, PhD., tenured professor at the University of Colorado, stated, “This patent represents the first method for treating drug resistant cancer using metabolic disruption, an approach targeting the distinct cancer-specific metabolic activities that can distinguish cancer cells in general, and many drug resistant cancer types, in specific, from normal cells in normal tissues.”

She continued, “We are very excited that the Patent Office has recognized the significance of work we first pioneered over eight years ago. The scientific community is now coming to accept the approach, metabolic disruption, as an extremely promising method for helping cancer patients.”

The new drug

...

TeamStaff, Inc., a national provider of healthcare, logistics and administrative staffing services, announced earlier today that its travel nurse and allied healthcare staffing division, TeamStaff Rx, Inc., has entered into an agreement with one of the nation’s largest healthcare services networks devoted exclusively to cancer treatment and research. Under the terms of the agreement, TeamStaff Rx will join a select number of companies to provide temporary healthcare professionals.

TeamStaff’s President and CEO, Rick Filippelli, commented, “This provides TeamStaff Rx with an enormous opportunity as well as a competitive advantage in growing our business and in taking a large step forward in being recognized as a leading provider of oncology staffing services to facilities throughout the country.”

The stock closed at $2.30, up 15%, on 6,558 traded shares today. With a 52-week range of $1.03 - $3.30, the stock’s average daily volume is 1,900 traded shares.

Let us hear your thoughts below:

In today’s pharmaceutical world, one needs to be fast off the mark. It is just a few hours old, but there may still be time to catch this one as investors make their choices. Prostate cancer treatment products are the next Lipitor, do your research and think about it.

Dendreon Corporation, a biotechnology company, works to develop and commercialize biotechnology therapeutics that enhance cancer treatment options. The company has several products in its product development pipeline with a prostate product making very successful progress in late stage approvals.

As we’ve stated in the past, there is a rush for larger pharmaceutical companies to refill their product pipelines. Although the supply of companies with later stage products, to fulfill this need, are growing smaller, there are still companies that fit the bill. Dendreon Corp. seems to be one of these companies as its prostate product makes solid headway toward approvals. Announced this morning,

...